Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of MG1113 in Healthy Subjects and Hemophilia Patients
NCT03855696Phase 1Completed
- Sponsor
- GC Biopharma
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MG1113 in hemophilia A and hemophilia B (HB) (3 arms), sponsored by GC Biopharma. Primary endpoint: Adverse events. Started Jan 2019; status: completed.
02
Drugs
MG1113
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03855696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855696.